1 / 20

Lighting the way ahead: novel approaches to breast cancer treatment with Xeloda

Lighting the way ahead: novel approaches to breast cancer treatment with Xeloda. Miguel Martin Hospital Universitario San Carlos Madrid, Spain. Novel treatment approaches with Xeloda. Metastatic breast cancer Sequential monotherapy All-oral regimens Novel schedules of administration

felice
Télécharger la présentation

Lighting the way ahead: novel approaches to breast cancer treatment with Xeloda

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lighting the way ahead:novel approaches to breast cancer treatment with Xeloda Miguel Martin Hospital Universitario San CarlosMadrid, Spain

  2. Novel treatment approaches with Xeloda Metastatic breast cancer • Sequential monotherapy • All-oral regimens • Novel schedules of administration Adjuvant/neoadjuvant trials • Combined with taxanes and anthracyclines • Replacing anthracyclines in adjuvant treatment • Maintenance chemotherapy post adjuvant • Elderly patients

  3. MOSG study design: first-line Xeloda and taxanes in combination and sequence RANDOMI ZAT ION n=345 XT: Xeloda 825mg/m2 b.i.d., d1–14 Taxotere 75mg/m2 on day 1, q21d (n=71) XP: Xeloda 825mg/m2 b.i.d., d1–14 paclitaxel 175mg/m2 on day 1, q21d (n=73) docetaxel 100mg/m2q3w (n=21) Xeloda1250mg/m2 b.i.d.d1–14, q21d (n=62) PD paclitaxel 175mg/m2q3w (n=4) PD = disease progression MOSG = Mexican Oncology Study Group Torrecillas L et al. Breast Cancer Res Treat 2004;88(Suppl. 1):S200 (Abst 5048)

  4. Patient characteristics:baseline metastases Torrecillas L et al. Breast Cancer Res Treat 2004;88(Suppl. 1):S200 (Abst 5048)

  5. First-line Xeloda: highly effective in combination and sequence with taxanes *Includes only responses achieved after Xeloda monotherapy†Time to PD on Xeloda if no further treatment given or time to PD on sequential taxane treatment Torrecillas L et al. Breast Cancer Res Treat 2004;88(Suppl. 1):S200 (Abst 5048)

  6. Proposed CASCADE study evaluating Xeloda in sequence with a taxane in first-line MBC 3-weekly docetaxel 60–100mg/m2 or weekly paclitaxel 80mg/m2 Xeloda1250mg/m2 b.i.d.d1–14, q21d RANDO MIZATION PD n=700 1st-line MBC: HER2-negative ³12 months, post adjuvant treatment 3-weekly docetaxel 100mg/m2 or weekly paclitaxel 80mg/m2 Xeloda1250 or 1000mg/m2b.i.d., d1–14, q21d PD • Primary endpoint: time to second-line treatment failure (PD, death, withdrawal for any reason)

  7. All-oral regimens

  8. Phase I/II trials investigating Xeloda in all-oral combinations 1Findlay MP et al. Proc Am Soc Clin Oncol 2002;21:85b (Abst 2151) 2Chan S-C et al. Proc Am Soc Clin Oncol 2002;21:53b (Abst 2023) 3Nole F. Eur J Cancer 2003;1(Suppl. 5):S174 (Abst 575) 4Delacambre C et al. Ann Oncol 2004;15(Suppl. 3):iii42 (Abst 158P)

  9. CYCLOX2: phase II New Zealand study evaluating Xeloda plus oral cyclophosphamide in MBC RANDO MI ZATION Xeloda 665mg/m2 b.i.d.continuously + oral cyclophosphamide 100mg/m2d1–14, q28d n=80 £1 prior regimen for advanced breast cancer Prior adjuvant chemotherapy allowed Xeloda 665mg/m2 b.i.d. continuously • Primary endpoint: response rate

  10. Novel schedules of administration

  11. Building upon experience in colorectal cancer with alternative schedules • Standard Xeloda dosing: 1250mg/m2 b.i.d. d1–14, q21d, selected over continuous administration • favorable safety and TTP1 • small sample size (<40 patients in each arm) • applicable to breast cancer? • Alternative schedules evaluated in colorectal cancer • fixed daily dose of Xeloda (750 or 1000mg/m2 b.i.d., continuous administration) is feasible and well tolerated2 1Van Cutsem E et al. J Clin Oncol 2000;18:1337–45 2Lokich J et al. Cancer Invest 2004;22:713–7

  12. Spanish phase II trial:continuous versus standard Xeloda RANDO MIZATION n=80 (initial phase) Xeloda 1250mg/m2 b.i.d. d1–14, q3w (standard arm) MBC HER-2 negative up to 2 prior lines Xeloda 800mg/m2 b.i.d. d1–21, q3w (continuous arm) • Primary endpoint: incidence of HFS (H1: 50% vs 35%) • Secondary endpoints: RR, TTP • Similar dose intensities and cumulative doses

  13. Intensive evaluation in the adjuvant treatment of early BC (N=21244)

  14. Intensive ongoing evaluation of Xeloda as primary systemic therapy (PST) for BC

  15. GEPARQUATTRO: German cooperative group neoadjuvant study • Primary endpoint: 5-year disease-free survival • Herceptin given concomitantly in HER-2 positive patients for eight or 12 cycles (and up to 1 year postoperatively) n=1600 RANDO MIZATION T100 x4 24 weeks EC x4 24 weeks T75/X1800x4 T75 x4 36 weeks X1800 x4

  16. MINDACT: optimizing decision-making for adjuvant chemotherapy 1st randomization Assess clinical and genomic risk Clinical and genomic BOTH HIGH RISK DISCORDANTclinical and genomic risks Clinical and genomic BOTH LOW RISK RANDOMIZE decision-making Use clinical risk Use genomic risk High risk High risk Low risk Low risk Chemotherapy No chemotherapy MINDACT = Microarray In Node Negative Disease May Avoid Chemotherapy

  17. Adjuvant XT as a replacement for anthracycline-based chemotherapy 2nd randomization High-risk patients RANDOMIZE type of chemotherapy Anthracycline based treatment Xeloda/Taxotere (XT)

  18. GEICAM-CIBOMA trial: maintenance Xeloda after adjuvant chemotherapy RANDO MIZATION Xeloda 1000mg/m2 d1–14q3w x 8 cycles n=3538 Operable breast cancer Node+ ER/PR– Completed six cycles adjuvant anthracycline-based chemotherapy Observation • Primary endpoint: 5-year disease-free survival (DFS); 14.18% relative increase (59.77–64.30%; HR 0.8582)

  19. Ongoing trials evaluating Xeloda as adjuvant treatment for elderly patients XN = Xeloda plus vinorelbine

  20. Xeloda: improving the management of breast cancer through novel approaches • As a highly effective and well-tolerated agent, Xeloda is enabling new treatment approaches for both metastatic and early breast cancer • Novel approaches under investigation will provide further options for tailoring treatment and improving outcomes

More Related